Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

AKEBIA THERAPEUTICS, INC.

(AKBA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Akebia Therapeutics : Submits New Drug Application to FDA For Vadadustat For Anemia Due to Chronic Kidney Disease

03/30/2021 | 06:17am EDT


© MT Newswires 2021
All news about AKEBIA THERAPEUTICS, INC.
06/07CYCLERION THERAPEUTICS  : Announces Global Licensing Agreement with Akebia Thera..
AQ
06/04Cyclerion Signs Praliciguat Licensing Deal With Akebia, Commences Direct Priv..
MT
06/03AKEBIA THERAPEUTICS  : Reports Inducement Grants Under Nasdaq Listing Rule 5635(..
AQ
06/03AKEBIA THERAPEUTICS, INC.  : Submission of Matters to a Vote of Security Holders..
AQ
06/03AKEBIA THERAPEUTICS  : Announces Presentations at ERA-EDTA Virtual Congress 2021
PR
06/02AKEBIA THERAPEUTICS  : Reports Inducement Grants Under Nasdaq Listing Rule 5635(..
PR
06/01Akebia, Otsuka Say FDA Accepts New Drug Application for Anemia Drug Vadadusta..
MT
06/01AKEBIA THERAPEUTICS  : and Otsuka Announce FDA Acceptance for Filing of New Drug..
PU
06/01AKEBIA THERAPEUTICS, INC.  : Regulation FD Disclosure, Other Events, Financial S..
AQ
05/12AKEBIA THERAPEUTICS  : Reports First Quarter 2021 Financial Results and Highligh..
PU
More news
Financials (USD)
Sales 2021 209 M - -
Net income 2021 -214 M - -
Net cash 2021 220 M - -
P/E ratio 2021 -2,73x
Yield 2021 -
Capitalization 589 M 589 M -
EV / Sales 2021 1,77x
EV / Sales 2022 1,61x
Nbr of Employees 380
Free-Float 98,9%
Chart AKEBIA THERAPEUTICS, INC.
Duration : Period :
Akebia Therapeutics, Inc. Technical Analysis Chart | AKBA | US00972D1054 | MarketScreener
Technical analysis trends AKEBIA THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Average target price 6,57 $
Last Close Price 3,68 $
Spread / Highest target 172%
Spread / Average Target 78,6%
Spread / Lowest Target -18,5%
EPS Revisions
Managers and Directors
NameTitle
John P. Butler President, Chief Executive Officer & Director
David A. Spellman Chief Financial Officer, Treasurer & Senior VP
Adrian Adams Chairman
Steven K. Burke Chief Medical Officer & Senior Vice President
Michel Dahan Chief Operating Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
AKEBIA THERAPEUTICS, INC.31.43%589
GILEAD SCIENCES, INC.14.33%83 541
WUXI APPTEC CO., LTD.24.70%63 775
REGENERON PHARMACEUTICALS11.35%55 705
BIONTECH SE160.57%51 304
VERTEX PHARMACEUTICALS-20.52%48 628